Pregabalin
Peripheral Neuropathy
University of RochesterSmall moleculePhase 4 / ApprovedActive
A
82/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 73/ 100
- Competitive Position
- 95/ 100
Competitive context
30 Active assets in the Peripheral Neuropathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lidocaine University of Utah | Phase 4 | BBB |
Nabiximols VA Office of Research and Development | Phase 3 | BBB |
Xaliplatin Tanta University | Phase 3 | BBB |
Gabapentin Washington University School of Medicine | Phase 4 | BB |
Capsaicin Astellas Pharma Europe Ltd. | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Pregabalin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →